

Technology Advisory Committee D Interests Register

**Topic: Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease
[ID4043]**

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Ivan Koychev	Committee Member	Direct - financial	<ul style="list-style-type: none"> Dr Koychev received grant funding from Novo Nordisk for a study looking at the effects of semaglutide in preclinical Alzheimer's disease. Dr Koychev has also had speaker fees from Novo Nordisk. Eisai approached Dr Koychev to take part in an educational non-promotional podcast focused on the diagnosis, treatment, and prevention of Alzheimer's disease, for which he was offered speaker fees. Dr Koychev is medical advisor for digital healthcare companies focused on the detection and intervention in Alzheimer's disease (Five Lives, Cognetivity, Cognes, and Mantrah). 	15/04/2024	It was agreed that Dr Koychev would be partially excluded from discussions, and he attended part 1 only. Dr Koychev engaged in committee discussion to provide advice to the meeting because of his expert knowledge but was excluded from developing recommendations and decision-making on the matter relating to the interest. Involvement was limited to answering direct questions from the committee.
Professor David Meads	Committee Member	Direct – non-financial professional	The University of Leeds has received funding from Takeda for research in an unrelated area.	16/04/2024 06/11/2024	It was agreed that Professor Meads' declaration would not prevent him from participating

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					in discussions on this appraisal.
Dr Will Sullivan	Committee Member	Direct – financial	<p>- Dr Sullivan is an employee of a consultancy company that provides paid services to various pharmaceutical companies. Will has provided consultancy work through his employment for the intervention company and two potential competitor companies for this appraisal in the last 12 months.</p> <p>The details are as follows:</p> <ul style="list-style-type: none"> • Will is part of a team providing ongoing health economic consultancy services to Biogen concerning the technology zuranolone to treat post-partum depression. • In a previous role within the last 12 months, Will was part of a team providing consultancy services to Biogen concerning the technology tofersen to treat amyotrophic lateral sclerosis. • Will is part of a team providing ongoing health economic consultancy services to Eisai Canada concerning the technology lemborexant to treat insomnia. 	<p>16/04/2024</p> <p>06/11/2024</p>	It was agreed that Dr Sullivan's declarations would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> Will is part of a team providing ongoing health economic consultancy services to Novartis concerning the technology asciminib to treat newly diagnosed chronic myelogenous leukemia. <p>- Between March 2024 and August 2024, Dr Sullivan was part of the team providing consultancy support to Novartis, helping to the team to prepare for the US launch of acsiminib for newly diagnosed chronic myelogenous leukemia, for which the company Will is employed by received payment.</p>	16/10/2024	
Dr Matthew Bradley	Committee Member	Direct - Financial	Dr Bradley's company GSK, in partnership with the Biotech Alector, has recently announced that they have an experimental medicine (AL101/GSK4527226) in Phase 2 development for early Alzheimer's Disease. In addition, they have a Phase 3 study completing in a rare form of dementia (frontotemporal dementia).	15/04/2024 11/10/2024	It was agreed that Dr Bradley's declaration would prevent him from participating in discussions on this appraisal.
Dr Jacoline Bouvy	NICE Programme Director - Medicines Evaluation	Direct – Professional	Dr Bouvy is co-author of the Landeiro et al 2020 paper which is referenced in the company submission as well as the EAG report.	09/05/2024	It was agreed that Dr Bouvy's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Elizabeth Coulthard	Clinical expert	Direct – financial	Professor Coulthard has been paid as a consultant and to provide educational resources by Eisai, Biogen, and Eli Lilly.	09/05/2024 06/11/2024	It was agreed that Professor Coulthard's declaration would not prevent her from providing expert advice to the committee.
Dr Richard Perry	Clinical expert	Direct – financial	<ul style="list-style-type: none"> Dr Perry has done consultancy and advisory work for Eisai and Biogen. Dr Perry is the Principal Investigator on clinical trials for lecanemab and for other amyloid targeted therapies. Dr Perry has lectured at Alzheimer's Research UK events. 	06/11/2024	It was agreed that Dr Perry's declaration would not prevent him from providing expert advice to the committee.
David Thomas	Patient expert	Direct – financial	David is employed by his nominating organisation, Alzheimer's Research UK. A small proportion of the organisation's income comes from pharma companies.	09/05/2024 06/11/2024	It was agreed that David's declaration would not prevent him from providing expert advice to the committee.
Larry Woelk	Patient expert	Direct - professional	Larry has been nominated by Alzheimer's Research UK and provided input for the organisation's submission to NICE.	06/11/2024	It was agreed that Larry's declaration would not prevent him from providing expert advice to the committee.